Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.

Antimicrob Agents Chemother

Johnson & Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202 South, Raritan, NJ 08869, USA.

Published: October 2010

Single-step Pseudomonas aeruginosa mutants, selected with ceftobiprole, ceftazidime, or cefepime, were generated at frequencies of 10(-6) to <10(-9) at two and four times the MIC. The chromosomal AmpC β-lactamase activity was increased in all ceftazidime-selected mutants. Mutants selected with cefepime either increased AmpC activity or upregulated expression of the mexXY efflux genes. Mutants selected with ceftobiprole did not overexpress AmpC; 90% of these produced elevated levels of mexXY RNA, indicating that increased efflux, not AmpC derepression, is the predominant response to ceftobiprole during first-step mutations in P. aeruginosa.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944577PMC
http://dx.doi.org/10.1128/AAC.00060-10DOI Listing

Publication Analysis

Top Keywords

pseudomonas aeruginosa
8
differential selection
4
selection single-step
4
single-step ampc
4
ampc efflux
4
efflux mutants
4
mutants pseudomonas
4
aeruginosa cefepime
4
cefepime ceftazidime
4
ceftazidime ceftobiprole
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!